Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

Eli Lilly (NYSE:LLY) is taking the unusual step of asking people who took compounded versions of their drug tirzepatide, marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes, for ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting. ... Chief Medical Officer, Lilly.

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound ...

Health news highlights the booming demand for obesity drugs in India with companies like Eli Lilly and Novo Nordisk vying for ...

The new Lilly alliance is one of three that Sidekick expects to announce in the coming months. If you liked this news story, check out the related video below. Image ...

The health sector is witnessing notable developments, including the rising demand for obesity drugs in India as Eli Lilly and ...